Halozyme Appoints Interim CFO David Ramsay
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy HALO?
Source: seekingalpha
- Interim CFO Appointment: Halozyme Therapeutics announced that David Ramsay will serve as interim CFO starting March 23, 2026, overseeing all financial operations to ensure continuity during the search for a permanent CFO.
- Extensive Financial Background: Ramsay previously held the CFO position from 2003 to 2009 and again from 2013 to 2015, during which time the company transitioned from a private entity to a billion-dollar public biopharmaceutical firm, highlighting his deep expertise in capital markets.
- Executive Search Underway: The company stated that the search for a permanent CFO is actively progressing, having engaged a leading executive search firm to identify candidates with a blend of capital markets expertise and strategic insight, thereby enhancing the company's financial leadership.
- Market Reaction: Following the announcement, Halozyme's stock price fell 0.88% in pre-market trading to $65.89, reflecting market caution regarding the changes in interim management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 61.630
Low
56.00
Averages
78.50
High
90.00
Current: 61.630
Low
56.00
Averages
78.50
High
90.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme Appoints Interim CFO David Ramsay
- Interim CFO Appointment: Halozyme Therapeutics announced that David Ramsay will serve as interim CFO starting March 23, 2026, overseeing all financial operations to ensure continuity during the search for a permanent CFO.
- Extensive Financial Background: Ramsay previously held the CFO position from 2003 to 2009 and again from 2013 to 2015, during which time the company transitioned from a private entity to a billion-dollar public biopharmaceutical firm, highlighting his deep expertise in capital markets.
- Executive Search Underway: The company stated that the search for a permanent CFO is actively progressing, having engaged a leading executive search firm to identify candidates with a blend of capital markets expertise and strategic insight, thereby enhancing the company's financial leadership.
- Market Reaction: Following the announcement, Halozyme's stock price fell 0.88% in pre-market trading to $65.89, reflecting market caution regarding the changes in interim management.
See More
Halozyme Appoints New Interim CFO David Ramsay
- Executive Appointment: Halozyme announced the appointment of David Ramsay as Interim Chief Financial Officer effective March 23, 2026, overseeing all financial operations until a permanent CFO is found, indicating the company's commitment to financial stability and continuity.
- Extensive Experience: Ramsay brings over 30 years of strategic financial leadership in the biotechnology and life sciences sectors, having served as Halozyme's CFO from 2003 to 2009 and again from 2013 to 2015, during which he guided the company from a private entity to a billion-dollar public biopharmaceutical firm, showcasing his deep expertise in capital markets.
- Strategic Priorities: CEO Dr. Helen Torley noted that Ramsay's return will have an immediate impact on advancing the company's strategic priorities, emphasizing his expertise in capital markets and investor relations, which is expected to enhance the company's competitive position in the market.
- Ongoing Executive Search: Halozyme is actively searching for a permanent CFO and has engaged a leading executive search firm to identify candidates with capital markets expertise and strategic capabilities, reflecting the company's focus on securing strong financial leadership for future growth.
See More
Halozyme Appoints New Interim CFO David Ramsay
- Executive Appointment: Halozyme announced the appointment of David Ramsay as Interim Chief Financial Officer effective March 23, 2026, overseeing all financial operations until a permanent CFO is found, demonstrating the company's commitment to stable financial leadership.
- Extensive Experience: Ramsay brings over 30 years of strategic financial leadership in the biotechnology and life sciences sectors, having served as Halozyme's CFO from 2003 to 2009 and again from 2013 to 2015, during which the company evolved from a private entity to a billion-dollar public biopharmaceutical firm, highlighting his significant impact on the company's growth.
- Strategic Priorities: CEO Dr. Helen Torley emphasized that Ramsay's expertise in capital markets and investor relations will be crucial in advancing the company's strategic priorities, indicating a strong focus on future development.
- Ongoing Recruitment: The company is actively searching for a permanent CFO and has engaged a leading executive search firm to identify candidates with capital markets expertise and strategic capabilities, ensuring alignment with the company's long-term growth objectives.
See More
Halozyme and Johnson & Johnson's Combination Therapy Approved
- FDA Approval: Halozyme Therapeutics announced that Johnson & Johnson's Tecvayli in combination with Darzalex Faspro has received FDA approval for adults with relapsed or refractory multiple myeloma who have had at least one prior therapy, marking a significant advancement in treatment options.
- Clinical Trial Success: The approval is based on positive results from the MajesTEC-3 study, which demonstrated that the combination significantly improved progression-free and overall survival, reducing the risk of disease progression or death by 83% compared to standard treatments after a median follow-up of three years.
- Market Reaction: Despite the approval of the new therapy, Halozyme's stock closed down 3.8% at $67.36 on Thursday, reflecting a cautious market sentiment regarding the company's future performance, which may impact investor confidence.
- Strategic Implications: This approval not only strengthens Halozyme's market position in multiple myeloma treatment but also showcases the potential of its ENHANZE drug delivery technology through collaboration with Johnson & Johnson, potentially laying the groundwork for future product development and market expansion.
See More
FDA Approves Halozyme and Johnson & Johnson's TECVAYLI for Multiple Myeloma
- FDA Approval: Johnson & Johnson's TECVAYLI® in combination with DARZALEX FASPRO® has received FDA approval for treating adults with relapsed or refractory multiple myeloma who have had at least one prior therapy, marking a significant advancement in treatment options.
- Clinical Trial Success: Based on data from the MajesTEC-3 study, the combination therapy demonstrated an 83% progression-free survival rate after a median follow-up of three years, significantly reducing the risk of disease progression or death by 83% compared to standard treatments, providing patients with a more effective option.
- Innovative Treatment Method: Both TECVAYLI and DARZALEX FASPRO are administered subcutaneously, simplifying the treatment process and enhancing patient convenience, aligning with modern healthcare's focus on patient experience.
- Broad Market Potential: This approval not only elevates Halozyme's position in the biopharmaceutical sector but may also drive further applications of its ENHANZE® technology, enhancing the company's competitiveness in the global market.
See More
FDA Approves Halozyme and Johnson & Johnson's TECVAYLI for Multiple Myeloma Treatment
- FDA Approval: Johnson & Johnson's TECVAYLI in combination with DARZALEX FASPRO has received FDA approval for treating adults with relapsed or refractory multiple myeloma who have had at least one prior therapy, marking a significant advancement in treatment options.
- Significant Clinical Results: Based on data from the MajesTEC-3 study, the combination therapy demonstrated an 83% progression-free survival rate after a median follow-up of three years, with an 83% reduction in the risk of disease progression or death compared to standard treatments, highlighting its clinical superiority.
- Innovative Administration: Both TECVAYLI and DARZALEX FASPRO are administered subcutaneously, offering a more convenient delivery method that aims to enhance patient experience and improve adherence to treatment, aligning with modern healthcare trends towards patient-friendly solutions.
- Broad Market Potential: This approval not only strengthens Halozyme's position in the biopharmaceutical sector but also may drive further applications of its ENHANZE technology, potentially attracting more pharmaceutical partnerships and expanding market share.
See More
Halozyme Appoints Interim CFO David Ramsay
- Interim CFO Appointment: Halozyme Therapeutics announced that David Ramsay will serve as interim CFO starting March 23, 2026, overseeing all financial operations to ensure continuity during the search for a permanent CFO.
- Extensive Financial Background: Ramsay previously held the CFO position from 2003 to 2009 and again from 2013 to 2015, during which time the company transitioned from a private entity to a billion-dollar public biopharmaceutical firm, highlighting his deep expertise in capital markets.
- Executive Search Underway: The company stated that the search for a permanent CFO is actively progressing, having engaged a leading executive search firm to identify candidates with a blend of capital markets expertise and strategic insight, thereby enhancing the company's financial leadership.
- Market Reaction: Following the announcement, Halozyme's stock price fell 0.88% in pre-market trading to $65.89, reflecting market caution regarding the changes in interim management.
See More
Halozyme Appoints New Interim CFO David Ramsay
- Executive Appointment: Halozyme announced the appointment of David Ramsay as Interim Chief Financial Officer effective March 23, 2026, overseeing all financial operations until a permanent CFO is found, indicating the company's commitment to financial stability and continuity.
- Extensive Experience: Ramsay brings over 30 years of strategic financial leadership in the biotechnology and life sciences sectors, having served as Halozyme's CFO from 2003 to 2009 and again from 2013 to 2015, during which he guided the company from a private entity to a billion-dollar public biopharmaceutical firm, showcasing his deep expertise in capital markets.
- Strategic Priorities: CEO Dr. Helen Torley noted that Ramsay's return will have an immediate impact on advancing the company's strategic priorities, emphasizing his expertise in capital markets and investor relations, which is expected to enhance the company's competitive position in the market.
- Ongoing Executive Search: Halozyme is actively searching for a permanent CFO and has engaged a leading executive search firm to identify candidates with capital markets expertise and strategic capabilities, reflecting the company's focus on securing strong financial leadership for future growth.
See More
Halozyme Appoints New Interim CFO David Ramsay
- Executive Appointment: Halozyme announced the appointment of David Ramsay as Interim Chief Financial Officer effective March 23, 2026, overseeing all financial operations until a permanent CFO is found, demonstrating the company's commitment to stable financial leadership.
- Extensive Experience: Ramsay brings over 30 years of strategic financial leadership in the biotechnology and life sciences sectors, having served as Halozyme's CFO from 2003 to 2009 and again from 2013 to 2015, during which the company evolved from a private entity to a billion-dollar public biopharmaceutical firm, highlighting his significant impact on the company's growth.
- Strategic Priorities: CEO Dr. Helen Torley emphasized that Ramsay's expertise in capital markets and investor relations will be crucial in advancing the company's strategic priorities, indicating a strong focus on future development.
- Ongoing Recruitment: The company is actively searching for a permanent CFO and has engaged a leading executive search firm to identify candidates with capital markets expertise and strategic capabilities, ensuring alignment with the company's long-term growth objectives.
See More
Halozyme and Johnson & Johnson's Combination Therapy Approved
- FDA Approval: Halozyme Therapeutics announced that Johnson & Johnson's Tecvayli in combination with Darzalex Faspro has received FDA approval for adults with relapsed or refractory multiple myeloma who have had at least one prior therapy, marking a significant advancement in treatment options.
- Clinical Trial Success: The approval is based on positive results from the MajesTEC-3 study, which demonstrated that the combination significantly improved progression-free and overall survival, reducing the risk of disease progression or death by 83% compared to standard treatments after a median follow-up of three years.
- Market Reaction: Despite the approval of the new therapy, Halozyme's stock closed down 3.8% at $67.36 on Thursday, reflecting a cautious market sentiment regarding the company's future performance, which may impact investor confidence.
- Strategic Implications: This approval not only strengthens Halozyme's market position in multiple myeloma treatment but also showcases the potential of its ENHANZE drug delivery technology through collaboration with Johnson & Johnson, potentially laying the groundwork for future product development and market expansion.
See More
FDA Approves Halozyme and Johnson & Johnson's TECVAYLI for Multiple Myeloma
- FDA Approval: Johnson & Johnson's TECVAYLI® in combination with DARZALEX FASPRO® has received FDA approval for treating adults with relapsed or refractory multiple myeloma who have had at least one prior therapy, marking a significant advancement in treatment options.
- Clinical Trial Success: Based on data from the MajesTEC-3 study, the combination therapy demonstrated an 83% progression-free survival rate after a median follow-up of three years, significantly reducing the risk of disease progression or death by 83% compared to standard treatments, providing patients with a more effective option.
- Innovative Treatment Method: Both TECVAYLI and DARZALEX FASPRO are administered subcutaneously, simplifying the treatment process and enhancing patient convenience, aligning with modern healthcare's focus on patient experience.
- Broad Market Potential: This approval not only elevates Halozyme's position in the biopharmaceutical sector but may also drive further applications of its ENHANZE® technology, enhancing the company's competitiveness in the global market.
See More
FDA Approves Halozyme and Johnson & Johnson's TECVAYLI for Multiple Myeloma Treatment
- FDA Approval: Johnson & Johnson's TECVAYLI in combination with DARZALEX FASPRO has received FDA approval for treating adults with relapsed or refractory multiple myeloma who have had at least one prior therapy, marking a significant advancement in treatment options.
- Significant Clinical Results: Based on data from the MajesTEC-3 study, the combination therapy demonstrated an 83% progression-free survival rate after a median follow-up of three years, with an 83% reduction in the risk of disease progression or death compared to standard treatments, highlighting its clinical superiority.
- Innovative Administration: Both TECVAYLI and DARZALEX FASPRO are administered subcutaneously, offering a more convenient delivery method that aims to enhance patient experience and improve adherence to treatment, aligning with modern healthcare trends towards patient-friendly solutions.
- Broad Market Potential: This approval not only strengthens Halozyme's position in the biopharmaceutical sector but also may drive further applications of its ENHANZE technology, potentially attracting more pharmaceutical partnerships and expanding market share.
See More
